[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bowel-preparation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bowel-preparation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,76,108,139,161,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643906","phase-3-evaluation-of-a-modified-bowel-preparation-regimen-in-cirrhotic-patients-undergoing-colonoscopy-100643906",false,"NCT07668778","Evaluation of a Modified Bowel Preparation Regimen in Cirrhotic Patients Undergoing Colonoscopy","Evaluation of a Modified Bowel Preparation Regimen in Cirrhotic Patients Undergoing Colonoscopy: a Multicentre Randomized Controlled Trial","CIRRHOPREP","Inclusion Criteria:\n\n* Established diagnosis of cirrhosis, scheduled for elective outpatient total colonoscopy\n* Age ≥ 18 years\n* Ability to follow verbal and written instructions in Portuguese\n\nExclusion Criteria:\n\n* Urgent procedures\n* Colonoscopies not intended to reach the caecum\n* History of any colonic surgery\n* Absolute contraindication to bowel preparation or colonoscopy\n* Active hepatic encephalopathy (West Haven grade ≥2) at the time of enrolment\n* Refractory ascites, defined as ascites unresponsive to maximum diuretic therapy or requiring repeated large-volume paracentesis\n* Severe hyponatraemia (serum sodium \\\u003C125 mEq\u002FL) at the time of enrolment\n* Subject refusal or inability to comprehend the trial","ALL","18 Years",{"count":20,"type":21},252,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Inadequate bowel preparation compromises colonoscopy quality and diagnostic accuracy, and cirrhosis is a recognized independent predictor of poor bowel cleansing. However, no bowel preparation regimen has been prospectively validated or specifically tailored for cirrhotic patients.\n\nThis multicenter, prospective, randomized, single-blind controlled clinical trial will evaluate whether the addition of adjunctive measures as an intensified bowel preparation protocol improves bowel cleansing quality in adult patients with cirrhosis undergoing elective outpatient colonoscopy.\n\nParticipants will be randomized 1:1 to receive either a standard bowel preparation protocol, consisting of a 2-litre split-dose polyethylene glycol (PEG) regimen combined with a one-day low-residue diet and clear liquids the afternoon before the procedure (control), or the same split-dose regimen with the assigned adjunctive measures: 15 mg bisacodyl, a 3-day low-residue diet, and clear liquids the day before colonoscopy (intervention).\n\nThe primary outcome is the proportion of patients achieving adequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) total score ≥6 with no individual segment score \\\u003C2. Secondary outcomes include polyp, adenoma, advanced adenoma and colorectal cancer detection rates, caecal intubation rate, patient compliance, tolerability, and adverse events. Pre-specified subgroup analyses will evaluate the influence of etiology and severity of cirrhosis and portal hypertension complications.\n\nBy addressing a critical and unmet clinical need, this trial aims to generate high-quality evidence to optimize bowel preparation strategies in patients with cirrhosis, improve colonoscopy quality, and ultimately enhance colorectal cancer screening outcomes in this vulnerable population.",[27,28],"Cirrhosis","Bowel Preparation",[30,27],"Inadequate bowel preparation","NOT_YET_RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-25","ACTUAL",{"date":37,"type":21},"2026-08-01",{"date":39,"type":21},"2027-10-30",{"name":41,"class":42},"Hospital do Divino Espírito Santo de Ponta Delgada","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100371208","phase-1-study-assessing-clenpiq-as-bowel-preparation-for-pediatric-colonoscopy-100371208","NCT04113382","Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy","A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years","PICCOLO","Inclusion Criteria:\n\n* Male or female, aged 2 years to \\\u003C9 years being scheduled to undergo elective colonoscopy.\n* Weight ≥10 kg (≥22 lbs).\n* Participants must have had an average of three or more spontaneous bowel movements (SBM) per week for 1 month prior to the colonoscopy.\n* Written informed consent (by parent(s)\u002F caregiver(s)\u002F guardian(s)) and assent (if applicable) obtained at screening.\n\nExclusion Criteria:\n\n* History of significant liver, cardiovascular, or renal disease (including recent or ongoing oliguria).\n* Acute surgical abdominal conditions (e.g., acute obstruction or perforation) during the screening period.\n* Clinically significant abdominal pain during the screening period.\n* Severe acute inflammatory bowel disease (IBD) during the screening period.\n* Any prior colorectal surgery, excluding appendectomy and polyp removal.\n* History of colon disease (e.g., Hirschsprung disease, volvulus, idiopathic pseudo-obstruction, or hypomotility syndrome).\n* History of or ongoing intestinal ulceration, toxic megacolon or other toxic colitis.\n* History of upper gastrointestinal disorder (e.g., active ulcer, pyloric stenosis or other cause of gastric retention, gastroparesis, or ileus).\n* History of upper gastrointestinal surgery (e.g., gastric resection or gastric bypass), excluding cholecystectomy.\n* Chronic or persistent, severe nausea or vomiting during the screening period.\n* Moderate to severe dehydration during the screening period.\n* Prior history of epileptic reaction, convulsions, or seizures.\n* Any clinically relevant neurological events with or without association with hyponatremia during the screening period.\n* Serum creatinine, estimated glomerular filtration rate (eGFR), potassium, or sodium outside normal limits during the screening period.\n* Hypermagnesemia during the screening period.\n* Use of the following prohibited medication: lithium (within 48 hours prior to procedure), laxatives (within 24 hours prior to procedure), drugs that in the opinion of the investigator are causing constipation in the participant (within 48 hours prior to procedure), antidiarrheal drugs (within 72 hours prior to procedure), or oral iron preparations (within 1 week prior to procedure).\n* Participation in an interventional investigational trial requiring administration of an investigational drug within 30 days prior to receiving trial medication (or within 60 days for investigational drugs with an elimination half-life \\>15 days).\n* Any clinically relevant abnormal findings in medical history, physical examination, vital signs, electrocardiogram (ECG), clinical chemistry, hematology, coagulation, or urinalysis at screening which in the opinion of the investigator(s), might put the participant at risk because of his\u002Fher participation in the trial.\n* Hypersensitivity to any of the ingredients of the trial medications.\n* Inability to comply with the dietary restrictions in the trial or the fluid requirements before and after investigational medicinal product (IMP) administration.","2 Years","8 Years",{"count":55,"type":21},30,[57,58],"PHASE1","PHASE2","Bowel preparation for pediatric colonoscopy.",[28],[62,63],"Colon Cleansing","Preparation for Colonoscopy","RECRUITING","2026-04-08",{"date":67,"type":35},"2026-04-09",{"date":69,"type":35},"2022-06-23",{"date":71,"type":21},"2027-06",{"name":73,"class":74},"Ferring Pharmaceuticals","INDUSTRY",5,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100613229","enhanced-ward-rounds-for-bowel-preparation-quality-in-hospitalized-patients-undergoing-colonoscopy-100613229","NCT07263867","Enhanced Ward Rounds for Bowel Preparation Quality in Hospitalized Patients Undergoing Colonoscopy","Effect of Increased Frequency of Resident Ward Rounds on Bowel Preparation Quality in Hospitalized Patients Undergoing Therapeutic Colonoscopy: A Cluster-Randomized Crossover Trial","ENHANCE-BP","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalized patients (inpatients)\n3. Scheduled for therapeutic colonoscopy (polypectomy, endoscopic mucosal resection \\[EMR\\], endoscopic submucosal dissection \\[ESD\\], or biopsy for diagnosis)\n4. Time from admission to scheduled colonoscopy ≥48 hours (allowing adequate preparation time)\n5. Patient or legal representative able to provide written informed consent\n6. Able to understand and follow bowel preparation instructions (with assistance from caregivers if needed)\n\nExclusion Criteria:\n\n1. Emergency gastrointestinal conditions: bowel obstruction, acute lower gastrointestinal bleeding requiring urgent intervention, suspected or confirmed perforation\n2. Emergency or same-day colonoscopy (scheduled \\\u003C24 hours after admission)\n3. History of total colectomy or current colostomy\u002Fileostomy\n4. Severe cognitive impairment (Mini-Cog score 0-1 or MMSE \\\u003C18) without available caregiver\n5. Severe cardiopulmonary disease: New York Heart Association (NYHA) Class IV heart failure, chronic kidney disease (CKD) stage 4-5 (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m²) unable to tolerate PEG-based preparation\n6. Known or suspected pregnancy, currently breastfeeding\n7. Previous severe allergic reaction to PEG or bowel preparation agents\n8. Current participation in another interventional clinical trial\n9. Unable to provide informed consent and no legal representative available\n10. Patient or legal representative declines participation",{"count":85,"type":21},300,[87],"NA","Adequate bowel preparation is critical for successful colonoscopy, yet inadequate preparation remains a significant clinical challenge, occurring in 20-30% of procedures. In hospitalized patients undergoing therapeutic colonoscopy, suboptimal preparation leads to increased costs, prolonged hospital stay, and potential procedure cancellation or rescheduling. Current standard care involves resident ward rounds twice daily.\n\nThis cluster-randomized crossover trial aims to evaluate whether increasing the frequency of structured resident ward rounds from 2 to 4 times per day can improve bowel preparation quality in hospitalized patients scheduled for therapeutic colonoscopy. The enhanced ward round intervention includes standardized checklist review, medication verification, dietary compliance confirmation, adverse event screening, and timely intervention when needed.\n\nThree hospital wards will be randomly assigned to different sequences of intervention and control periods using a crossover design with washout periods. The primary outcome is adequate bowel preparation quality assessed by Boston Bowel Preparation Scale (BBPS ≥6 with each segment ≥2), evaluated by blinded endoscopists. Secondary outcomes include procedure quality metrics (cecal intubation rate, examination duration), safety endpoints (electrolyte disturbances, aspiration events), health economics measures (length of stay, total costs), and healthcare worker burden (nursing workload, night-time call frequency).\n\nSubgroup analyses will examine intervention effects across age groups, cognitive function levels, prior colonoscopy experience, and comorbidity burden to identify populations most likely to benefit from enhanced monitoring.\n\nThis pragmatic trial addresses a clinically relevant question using a real-world implementation strategy designed to minimize workflow disruption. Results will inform evidence-based policies regarding optimal ward round frequency for colonoscopy preparation in hospital settings.",[90,28,91],"Colonoscopy","Quality of Healthcare",[93,94,95,96,97],"Bowel preparation","Ward rounds","Colonoscopy quality","Cluster randomized trial","Boston Bowel Preparation Scale","2026-03-04",{"date":100,"type":35},"2026-03-06",{"date":102,"type":21},"2026-03-28",{"date":104,"type":21},"2026-12-30",{"name":106,"class":42},"LanZhou University",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":17,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":107},"100606868","phase-3-a-study-to-evaluate-the-safety-and-effectiveness-of-msp01-t-for-bowel-cleansing-before-a-colonoscopy-100606868","NCT07181148","A Study to Evaluate the Safety and Effectiveness of MSP01-T for Bowel Cleansing Before a Colonoscopy","A Prospective, Randomized, Single-blinded (Investigator), Parallel, Multi-center, Active-control, Non-inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of MSP01-T for Bowel Cleansing Before Colonoscopy","MSP01","Inclusion Criteria:\n\n1. Male or female participants aged 19 years or older at the time of providing written informed consent.\n2. Individuals scheduled to undergo a screening colonoscopy.\n3. 19 kg\u002F㎡ ≤ BMI \\\u003C 30 kg\u002F㎡\n4. Participants who have voluntarily agreed to participate in the clinical trial and have provided written informed consent.\n\nExclusion Criteria:\n\nParticipants who meet any of the following will NOT be eligible to participate in this clinical trial:\n\n1. Colonoscopy for therapeutic purposes, including:\n\n   * Hemostatic treatment after vascular malformation, ulcer, tumor, or polypectomy\n   * Decompression for non-toxic megacolon or sigmoid volvulus\n   * Foreign body removal\n   * Balloon dilation of strictures\n   * Palliative treatment for bleeding due to strictures or tumors\n2. Medical history at screening, including:\n\n   * Epilepsy or seizure within 2 years\n   * Severe cardiac disease within 24 weeks (e.g., unstable angina, acute myocardial infarction)\n   * Clinically significant gastrointestinal or abdominal surgery within 24 weeks (except appendectomy, hemorrhoidectomy)\n   * Active infection or fever ≥ 38°C within 1 week (except mild upper respiratory infection or localized skin infection)\n   * Hypersensitivity to investigational product components\n3. Concomitant diseases at screening, including:\n\n   * Active gastrointestinal bleeding\n   * Coagulation disorders\n   * Gastrointestinal obstruction, perforation, or gastric emptying disorders\n   * Inflammatory bowel disease (e.g., Crohn's disease, toxic megacolon, toxic colitis)\n   * Acute abdomen requiring surgery\n   * Major cardiovascular disease (e.g., congestive heart failure \\[NYHA class III-IV\\], clinically significant arrhythmia, QTcF \\> 450 msec \\[male\\] or \\> 470 msec \\[female\\])\n   * Uncontrolled hypertension (systolic blood pressure \\> 170 mmHg or diastolic blood pressure \\> 100 mmHg)\n   * Insulin therapy requirement\n   * Clinically significant electrolyte imbalance\n   * Risk of dehydration (e.g., rhabdomyolysis, ascites)\n   * Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n   * ALT or AST \\> 3 × ULN\n   * Severe nausea or vomiting interfering with trial participation\n   * Active hepatitis B (HBsAg positive) or hepatitis C (HCV Ab positive)\n   * HIV positive\n   * Neurological or psychiatric disorders (e.g., depression, bipolar disorder, epilepsy, substance abuse) or use of related medications\n4. Medication use:\n\n   * Severe constipation (bowel movement \\\u003C 3\u002Fweek) or regular use of laxatives\u002Fprokinetics within 12 weeks\n   * Use of laxatives, enemas, simethicone, 5-HT4 agonists, iron, or opioids within 7 days before Day 1\n5. Pregnant or breastfeeding women\n6. Women of childbearing potential and men unwilling to use effective contraception during the study\n7. Participation in another clinical trial and receipt of investigational drug or device within 4 weeks\n8. Any condition judged inappropriate by the investigator",true,"19 Years",{"count":119,"type":21},214,[24],"This study is being conducted to evaluate the safety and effectiveness of MSP01-T, a new bowel cleansing agent, in adults who are scheduled to undergo a colonoscopy.\n\nParticipants will be randomly assigned to receive either MSP01-T or a comparator product.\n\nThe study will assess how effectively MSP01-T cleans the bowel before the procedure and monitor any potential side effects.\n\nAdults aged 19 years and older who are planning to have a colonoscopy may be eligible to take part.",[90,28],[124,90,125,126,127,128,129],"MSP01-T","Colon Cleanse","Oral Bowel Cleanser","Oral Tablet","Randomized Trial","Phase 3 Study","2025-09-24",{"date":132,"type":35},"2025-09-25",{"date":134,"type":21},"2025-10",{"date":136,"type":21},"2026-05",{"name":138,"class":74},"Mather's Pharm. Co., Ltd.",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100602724","early-phase-1-prucaloprida-vs-bisacodyl-as-a-stimulant-in-bowel-preparation-for-video-colonoscopy-in-adults-100602724","NCT07127237","Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults","Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults: A Randomized Clinical Trial","Inclusion Criteria:\n\n* All patients over 18 years of age.\n* Without prior colonic surgical interventions.\n* Who attend the Digestive Endoscopy service to undergo a colonoscopy.\n\nExclusion Criteria:\n\n* Patients who voluntarily choose not to participate in the study.\n* Pregnant women.\n* Patients with rectocolonic resections and\u002For ileostomies.\n* Inflammatory bowel disease.\n* Inadequate bowel preparation in a previous colonoscopy.\n* Suspected intestinal obstruction or perforation.\n* Intestinal intussusception.\n* Melena.\n* Oral iron intake within the last 10 days.\n* Emergency colonoscopies.\n* Hypersensitivity to any component of the bowel preparation solutions.\n* Chronic kidney disease on dialysis.\n* Uncorrected severe electrolyte imbalances.\n* Major psychiatric disorders.\n* Low intellectual quotient.\n* Severe constipation (≤ 1 bowel movement per week).\n* Chronic diarrhea with high frequency (≥ 4 daily bowel movements of uniformly decreased consistency for more than 4 weeks).\n* Decompensated cardiac diseases (ischemic heart disease, congestive heart failure, unstable angina, arrhythmias, and uncontrolled hypertension).\n* Ascites.",{"count":147,"type":21},124,[149],"EARLY_PHASE1","The objective of this randomized clinical trial is to compare prucalopride versus bisacodyl as a stimulant agent for bowel cleansing preparation prior to colonoscopy in patients undergoing the procedure at the Endoscopy Unit of the Hospital de Clínicas. The main research questions this study aims to answer are:\n\nIs prucalopride superior or equivalent to bisacodyl as a stimulant agent for bowel cleansing preparation before colonoscopy? Is the tolerability of prucalopride better, equivalent, or worse compared to bisacodyl? The investigators will compare the standard bowel cleansing preparation using polyethylene glycol (PEG) in combination with either bisacodyl or prucalopride as the stimulant agent.\n\nParticipants will be randomized into two groups, both receiving the same base preparation with different stimulant agents.",[28],"2025-08-11",{"date":154,"type":35},"2025-08-17",{"date":156,"type":21},"2025-09",{"date":158,"type":21},"2026-02",{"name":160,"class":42},"Hospital de Clínicas Dr. Manuel Quintela",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":107},"100585419","comparison-of-outcome-of-three-days-bowel-preparation-vs-no-bowel-preparation-in-patients-of-colostomy-reversal-100585419","NCT06902116","Comparison of Outcome of Three Days Bowel Preparation vs No Bowel Preparation in Patients of Colostomy Reversal","Inclusion Criteria:\n\n* Children with colostomy between 1-15 years of age\n\nExclusion Criteria:\n\n* Malnourished\n* Previous history of colostomy site anastomotic leakage","1 Year","15 Years",{"count":170,"type":21},80,[87],"The goal of this trial is to compare the outcomes of colostomy reversal with three days bowel preparation with no bowel preparation in terms of anastomotic leakage, surgical site infection and hospital stay.\n\nThe important question this trial aims to answer is:\n\n1\\. is there any difference in outcomes after colostomy reversal with three days gut preparation pre-operatively vs no gut preparation?\n\nThis prospective Randomized Controlled trial will include children with colostomy divided into two groups:\n\nGroup A: No Mechanical Bowel Preparation Group B: 3 Days Mechanical Bowel Preparation Participants of Group A will be admitted 1 day prior to surgery date as they require no special preparation before surgery. They will be made Nil per oral 6 hours prior to surgery. Group B participants will be admitted 3 days prior to surgery. These participants will be restricted to fiber rich diet and milk 72 hours prior to surgery. They will be shifted to clear liquids 24 hours prior to surgery. Normal saline enema will be given 8 hourly through the stoma as well as per rectally by the trained person.\n\nComparative outcomes will be:\n\n1. Anastomotic leakage\n2. Hospital Stay\n3. Wound infection",[174,28,175],"Colostomy - Stoma","BOWEL ANASTOMOSIS","2025-03-27",{"date":178,"type":35},"2025-03-30",{"date":180,"type":35},"2025-01-08",{"date":182,"type":21},"2026-03",{"name":184,"class":42},"University of Child Health Sciences and Children's Hospital, Lahore",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":107},"100560685","phase-4-comparing-sennosid-ab-and-sodium-picosulfatemagnesium-oxidecitric-acid-for-bowel-preparation-100560685","NCT06580366","Comparing Sennosid A+B and Sodium Picosulfate\u002FMagnesium Oxide\u002FCitric Acid for Bowel Preparation","Sennosid A+B Versus Sodium Picosulfate\u002FMagnesium Oxide\u002FCitric Acid for Bowel Preparation; A Prospective Randomized Observer-Blinded Study","Inclusion Criteria:\n\n* Adults aged 18-80 years scheduled for elective outpatient colonoscopy.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* History of intra-abdominal surgery.\n* Chronic kidney failure.\n* Congestive heart failure.\n* Chronic liver failure.\n* Inflammatory bowel disease.\n* Electrolyte imbalance.\n* Hospitalized patients.\n* Patients unable to use the bowel preparation treatment\n* Known allergy or hypersensitivity to Sennoside A+B or PM\u002FCa components\n* Known gastrointestinal motility disorders.","80 Years",{"count":194,"type":21},600,[196],"PHASE4","Colonoscopy Preparation: Comparing Sennoside A+B and PM\u002FCa\n\nColonoscopy is a test used to examine the inside of the bowel. Proper bowel preparation is crucial because it helps doctors get a clear view during the procedure.\n\nWhat is Sennoside A+B? Sennoside A+B is a type of laxative made from the senna plant. It works by stimulating the bowel to move and reducing the absorption of water, making it easier to pass stools. Research has shown that high doses of sennoside A+B can be effective for bowel preparation.\n\nSennoside A+B vs. PEG:\n\nSome studies have found that sennoside A+B is more effective than PEG, another laxative, but can cause more abdominal pain. Other studies have found no significant difference in effectiveness between the two.\n\nWhat is Picosulfate\u002FMagnesium Oxide\u002FCitric Acid (PM\u002FCa)? PM\u002FCa is a combination of sodium picosulfate, magnesium oxide, and citric acid. Sodium picosulfate stimulates bowel movements, while magnesium oxide and citric acid help increase water in the bowel, making it easier to pass stools.\n\nPM\u002FCa vs. PEG:\n\nResearch has shown that PM\u002FCa is as effective as PEG for bowel preparation. Patients using PM\u002FCa generally tolerate the preparation process better than those using PEG.\n\nConclusion:\n\nWhile PEG is the preferred option according to guidelines, its high cost can make it less accessible in some places. In this study, we aim to compare the effectiveness and patient tolerance of Sennoside A+B and PM\u002FCa since no direct comparison between these two preparations has been made before.",[28],[93,90,200,201],"sennosid A+B","Sodium Picosulfate","2024-08-28",{"date":204,"type":35},"2024-08-30",{"date":206,"type":21},"2024-08-22",{"date":208,"type":21},"2025-03-22",{"name":210,"class":42},"Hitit University"]